Combining PI3K and PARP inhibitors for breast and ovarian cancer treatment

Ann Oncol. 2017 Jun 1;28(6):1167-1168. doi: 10.1093/annonc/mdx218.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Breast
  • Breast Neoplasms
  • Female
  • Humans
  • Ovarian Neoplasms
  • Phosphatidylinositol 3-Kinases*
  • Phthalazines
  • Poly(ADP-ribose) Polymerase Inhibitors*

Substances

  • Phthalazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Phosphatidylinositol 3-Kinases